Trial Profile
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amylin Pharmaceuticals; AstraZeneca
- 29 Feb 2012 Results published in Diabetic Medicine.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.
- 16 Jul 2010 Planned end date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.